LETTERS TO THE EDITOR

Cerebral metabolism during vegetative state and after recovery to consciousness

One way to approach the study of consciousness is to explore lesional cases in which impairment of consciousness is the prominent clinical sign. Vegetative state is such a condition wherein awareness is abolished whereas arousal persists. It can be diagnosed clinically soon after a brain injury and may be reversible (as in the following case report) or progress to a persistent vegetative state or death. The distinction between vegetative state and persistent vegetative state is that the second is defined as a vegetative state that has continued or endured for at least 1 month.1 We present a patient who developed a vegetative state after carbon monoxide poisoning and in whom we had the opportunity to measure brain glucose metabolism during the vegetative state and after recovery to consciousness. Using [(18F)]fluorodeoxyglucose (FDG) PET and statistical parametric mapping (SPM) we compared both patient’s sets to a normal control population. Our findings offer an insight into the neural correlates of “awareness”, pointing to a critical role for posterior associative cortices in consciousness.

A 40 year old right handed woman attempted suicide through CO intoxication and was found unconscious. She was treated with hyperbaric oxygen but evolved to a vegetative state diagnosed according to the following criteria: (1) spontaneous eye opening without evidence of awareness of the environment; (2) no evidence of reproducible voluntary behavioural responses to any stimuli; (3) no evidence of language comprehension or expression; (4) intermittent wakefulness and behaviourally assessed sleep-wake cycles; (5) normal cardiorespiratory function and blood pressure control; (6) preserved pupillary, oculocephalic, corneal, and vestibulo-ocular reflexes. Brain MRI performed 14 days after admission was normal. Electroencephalography showed a 6 Hz basal activity with more pronounced slowing on the left parietal regions. Auditory evoked potentials of the median nerve showed normal latency and amplitude of P14 and N20 potentials without any late cortical components. After remaining in a vegetative state for 19 days the patient regained consciousness. Her sequelae consisted of a bilateral spastic paresis of upper and lower limbs. Neuropsychological examination 1 month after admission showed an attention deficit with moderate impairment of short term memory. One year after the accident she showed a spastic gait with altered fine motor function, most prominent on the right, a slurred speech, and minor short term memory disturbances. FDG-PET was performed during the vegetative state (day 15 after admission) and after recovery to consciousness (day 57).

The control population consisted of 48 drug free, healthy volunteers, aged from 18 to 76 years (mean: 42 (SD 21) years). The study was approved by the ethics committee of the University of Liège. Informed consent was obtained by the husband of the patient and for all control subjects. Five to 10 mCi FDG was injected intravenously; PET data were obtained on a Siemens CTI 951 R 16/31 scanner in bidimensional mode. Arterial blood samples were drawn during the whole procedure and cerebral metabolic glucose rates (CMRGlu) were calculated for all subjects. PET data were analysed using SPM software (SPM96 version; Welcome Department of Cognitive Neurology, Institute of Neurology, London, UK).2 The use of SPM to assess between subject (rather than within subject) variability is unlikely to alter the relevance of our results given their high degree of significance. Data from each subject were normalised to a standard stereotaxic space and then smoothed with a 16 mm full width half maximum isotropic kernel. The analysis identified brain regions where glucose metabolism was significantly lower in each patient scan compared with the control group. The resulting foci were characterised in terms of peak height over the entire volume analysed at a threshold of corrected p<0.05.

During the vegetative state, average grey matter glucose metabolism was 38% lower than in controls (4.5 ± 7.3 (SD 1.4) mg/100 g/min). No substantial change in mean CMRGlu was found after recovery (4.7 mg/100 g/min). During the vegetative state, significant regional CMRGlu decreases were found in the left and right superior parietal lobe; the left inferior parietal lobe; the precuneus; the left superior occipital, superior and middle temporal gyri; and the premotor and postcentral and precentral cortex (figure, yellow colour). After recovery, metabolic impairment was confined to the left and right precentral and postcentral gyri and premotor cortices (figure, blue colour).

This case report offers an insight into the neural correlates of human consciousness (at least, external awareness as it can be assessed at the patient's bedside). Given that global glucose utilisation levels remained essentially the same, the recovery of consciousness seems related to a modification of the regional distribution of brain function rather than to the global resumption of cerebral metabolism. The main decreases in metabolism seen during the vegetative state but not after recovery were found in parietal areas, including the precuneus. This is in agreement with postmortem findings in persistent vegetative state, in which involvement of the association cortices is reported as a critical neuroanatomical substrate3 and with PET studies in postanoxic syndrome, in which the parieto-occipital cortex showed the most consistent impairment.4 The functions of these areas are manifold: lateral parietal areas are involved in spatial perception and attention, working memory, mental imagery, and language, whereas the precuneus is activated in episodic memory retrieval, modulation of visual perception by mental imagery, and attention.5 Our data point to a critical role for these posterior associative cortices in the emergence of conscious experience.

STEVEN LAUREYS
CHRISTIAN LEMAIRE
PIERRE MAQUET
Cyclotron Research Centre, University of Liège, Sart Tilman, 4000 Liège, Belgium

CHRISTOPHE PHILLIPS
Institute of Cognitive Neurology, University College London, Alexandra House, 17 Queen Square, London WC1N3AR, England, UK

GEORGE FRANCK
Department of Neurology, CHU Liège Sart, Tilman B-35, 4000 Liège, Belgium
Correspondence to: Dr Pierre Maquet, Cyclotron Research Centre (B30), University of Liège, Sart Tilman, 4000 Liège, Belgium Telephone 0032 4 26 66 36 87; fax 0032 43 66 29 46; email maquet@pet.crc.ac.be


Localisation of voxels in which cerebral glucose metabolism was impaired during vegetative state (in yellow) and after recovery to consciousness (in blue), compared with the control population. SPM(2) threshold was set at voxel level corrected p<0.05 and projected on the patient’s coregistered MRI, normalised to the stereotaxic space of Talairach.

Downloaded from http://jnnp.bmj.com/ on April 4, 2017 - Published by group.bmj.com
Electrical inexcitability of nerves and muscles in severe infantile spinal muscular atrophy

Spinal muscular atrophy (SMA) is one of the most common fatal autosomal recessive disorders, characterised by progressive degeneration of anterior horn cells. Before the advent of genetic testing, the diagnosis of SMA was based on clinical, histopathological, and electrophysiological features. In 1992, the International SMA Consortium devised diagnostic criteria of proximal SMA based on clinical findings. In SMA type I (severe; Werdnig-Hoffmann disease), affected persons have onset of symptoms before 6 months of age and are never able to sit without support. The electromyography demonstrates denervation features. In early 1995, the candidate gene, the survival motor neuron (SMN) gene, was identified, making the confirmation of SMA by DNA analysis possible.

With the availability of a genetic test for SMA, many investigators are refining the diagnostic criteria published by the Consortium. Studies involving hundreds of patients with SMA have disclosed a subset of patients who fulfil at least one exclusion criterion defined by the Consortium. We identified an infant with severe SMA who fulfilled two exclusion criteria and also showed inexcitability of all nerves as well as muscles. This report will further delineate the wide range of phenotypes for this particular gene mutation.

A 5-month-old male infant was born at term. First fetal movements were noted at 13 weeks of gestation. Chorionic villus sampling at 10 weeks of gestation disclosed normal chromosomal decreases. Decreased fetal movement and polyhydramnios were noted at about 34 weeks of gestation. At delivery, the infant was cyanotic with no respiratory effort and was subsequently intubated. On physical examination, the infant had no spontaneous movements. He opened his eyes with brief fixation but no following. Tongue fasciculations were present. Other cranial nerves seemed intact. Mild flexion contractures of both elbows, knees, and ankles were noted. Tone was flaccid with hyperreflexic patellae and biceps brachii. There was no movement response to painful stimuli. Deep tendon reflexes were absent.

Brain MRI disclosed mild diffuse cortical atrophy. His EMG was severely abnormal, with widespread fibrillations and absent voluntary motor units except in the genioglossus, where mildly neurogenic motor unit potentials were present. DNA analysis disclosed the 5q deletion in both cases, DNA analysis disclosed the 5q deletion in both cases. In addition, these patients also exhibited one of the exclusion criteria defined by the Consortium—for example, diaphragmatic weakness and atrophy, hypotonia, and evidence of neuromuscular alterations in EMG and muscle biopsy. In addition, these patients also exhibited one of the exclusion criteria defined by the Consortium—for example, diaphragmatic weakness and atrophy, hypotonia, and evidence of neuromuscular alterations in EMG and muscle biopsy. In addition, these patients also exhibited one of the exclusion criteria defined by the Consortium—for example, diaphragmatic weakness and atrophy, hypotonia, and evidence of neuromuscular alterations in EMG and muscle biopsy. In addition, these patients also exhibited one of the exclusion criteria defined by the Consortium—for example, diaphragmatic weakness and atrophy, hypotonia, and evidence of neuromuscular alterations in EMG and muscle biopsy. In addition, these patients also exhibited one of the exclusion criteria defined by the Consortium—for example, diaphragmatic weakness and atrophy, hypotonia, and evidence of neuromuscular alterations in EMG and muscle biopsy. In addition, these patients also exhibited one of the exclusion criteria defined by the Consortium—for example, diaphragmatic weakness and atrophy, hypotonia, and evidence of neuromuscular alterations in EMG and muscle biopsy.

In SMA type I showed electrical inexcitability of motor nerves as well as the characteristic alteration of the SMN gene. Although it has been shown for some time that histological studies have been previously reported only once. Sensory nerve conduction velocity was tested in one of these patients with severe SMA and showed no recordable potential, but the infant in our report also exhibited universal absence of sensory potentials. In both cases, DNA analysis disclosed the 5q deletion. It is unclear whether this finding represents a distinct entity or merely the severe end of classic Werdnig-Hoffmann disease. The diagnostic criteria produced by the International SMA Consortium currently lists “abnormal sensory nerve conduction potentials” as an exclusion criterion. Our finding of absent sensory potentials in a 5q deletion established case of SMA indicates further need for revision of the Consortium criteria.

Studies involving larger numbers of patients with SMA have identified cases of SMA variants. These patients were diagnosed as infantile SMA by the presence of proximal weakness and atrophy, hypotonia, and evidence of neuromuscular alterations in EMG and muscle biopsy. In addition, these patients also exhibited one of the exclusion criteria defined by the Consortium—for example, diaphragmatic weakness and atrophy, hypotonia, and evidence of neuromuscular alterations in EMG and muscle biopsy. In addition, these patients also exhibited one of the exclusion criteria defined by the Consortium—for example, diaphragmatic weakness and atrophy, hypotonia, and evidence of neuromuscular alterations in EMG and muscle biopsy. In addition, these patients also exhibited one of the exclusion criteria defined by the Consortium—for example, diaphragmatic weakness and atrophy, hypotonia, and evidence of neuromuscular alterations in EMG and muscle biopsy. In addition, these patients also exhibited one of the exclusion criteria defined by the Consortium—for example, diaphragmatic weakness and atrophy, hypotonia, and evidence of neuromuscular alterations in EMG and muscle biopsy.

Although it has been known for some time that the severe denervation in SMA type I results in no clinical or electrical response. One possibility is that the severe denervation in SMA type I results in no clinical or electrical response. One possibility is that the severe denervation in SMA type I results in no clinical or electrical response. One possibility is that the severe denervation in SMA type I results in no clinical or electrical response. One possibility is that the severe denervation in SMA type I results in no clinical or electrical response.


Acute overdosage and intoxication with carbidopa/levodopa can be detected in the subacute stage by measurement of 3-α-methyltyrosine

Although the effects of a chronic overdosage with levodopa are well known, few cases of acute intoxication have been described. A particular problem in establishing a diagnosis of levodopa overdosage is that the effects of a single overdosage lasting half and less than half the life in the circulation of levodopa. If there is a delay in bringing an acutely intoxicated patient to hospital, perhaps due to late discovery, the blood concentration of levodopa could already be normal (as opposed to the peak levodopa concentration in Parkinson’s disease therapy) after 6–8 hours. Depending on the extent of the overdosage, the time could be even shorter. This report describes the clinical effects and the plasma concentrations of levodopa and specific metabolites over a period of 132.5 hours after ingestion of 30 tablets of carbidopa/levodopa (50 mg/200 mg tablets).

A 76 year old patient had a pre-existing mild akinetic rigid Parkinson’s syndrome, which had been treated for the past 1.5 years with 3×1 tablets of carbidopa/levodopa (50 mg/200 mg) a day without a substantial response. The weight of the patient was 74 kg. A known chronic obstructive airway disease was treated with a home oxygen appliance. At about 8.30 pm, the patient had attempted suicide by taking 8 tablets of carbidopa/levodopa. About 1 hour later, he was observed psychically altered, crying without reason, anxious, and depressed. After about 30 minutes he was increasingly inadequate, wan, cold, and subephaptic, and was experiencing visual hallucinations; he was restless, tossing and turning, and getting out of bed. He did not represent peak dose dyskinesia or other extrapyramidal clinical features. At 10.00 pm he showed bilaterally maximally dilated pupils. The muscle stretch reflexes were lively, there were no pyramidal tract signs, and he did not show any signs of Parkinson’s syndrome or dyskinesia. Arterial hypotension and sinus tachycardia could be registered.

After an empty box of Striaton (carbidopa/levodopa, 50 mg/200 mg) was found in the patient’s flat, 1 g of carbon was given by stomach tube after gastric lavage. This treatment was carried out before the diagnosis of intoxication had been made; it showed a pronounced subcortical arteriosclerotic encephalopathy with reduced brain volume. The patient was moved to the medical intensive care unit and observed for 24 hours. The ECG showed a P pulmonale, but no other unusual features. Echocardiography showed normal right and left ventricular function with suspicion of right ventricular hypertro-
Distribution into muscles rather than metabolism may largely determine the plasma half life of levodopa and explain why this was only slightly altered with overdose. The measured peak concentration of 66.763 ng/ml is about 30 times higher than the peak concentration to be expected after taking one tablet of carbidopa/levodopa (50 mg/200 mg). It is apparent that the 30 tablets did not interfere with absorption or lead to a gastrointestinal paralysis due to the high dose of levodopa; the relation between amount ingested and plasma concentration seems to be linear, at least in this dose range.

We conclude from these findings that in cases of suspected levodopa intoxication some hours previously, it could be important to measure the concentration of 3-o-methyldopa, so as not to overlook an overdosage with levodopa, which may be due to a suicide attempt. In addition to the diagnostic uncertainty in relation to the immediate treatment of the patient, this would also have an effect on further psychiatric and psychological therapy.

**The use of olanzapine for movement disorder in Huntington’s disease: a first case report**

Movement disorder is a prominent feature of Huntington’s disease and consists of involuntary and voluntary components as well as associated bradykinesia. Pharmacological treatment is problematic because of the side effects of the drugs used, which may further compromise cognitive functioning and mobility. Patients are often not subjectively aware of their movements but can be considerably disabled by them and carers are often distressed and enquire about treatment options. If drug treatment is considered it is important to achieve the maximum improvement in movements with the minimum of negative side effects. This paper describes the effect of olanzapine on movements when drug treatment is problematic because of the side effects. This paper describes the effect of olanzapine on movements when drug treatment is problematic because of the side effects.

H J STUERENBURG

EG H SCHÖSER

Correspondence to: Dr Hans Joerg Stuermann, Neurological Department, University Hospital Hamburg-Eppendorf, Hamburg, Germany

Published by BMJ Publishing Group. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions


**References**


risperidone. This was started at a dose of 1 mg twice daily, increasing to a dose of 1 mg four times a day over a period of 2 weeks, stopped after a brief period. He developed hypotension (blood pressure 100/60 mm Hg), complaining of dizziness after the initial dose. His blood pressure remained stable, although low, after this and as there was improvement in his movements the drug was continued. However, he decided to stop the risperidone after 4 months because of his subjective experience of slowed thinking and occasional dizziness. A repeated trial of sulpiride was carried out in March 1997. Sulpiride was started at a dose of 200 mg twice a day and increased to a total daily dose of 1000 mg over 2 weeks. He was on sulpiride for 4 weeks with no improvement in his movements, so it was discontinued. The patient continued to experience low mood and after the discontinuation of sulpiride, his antidepressant drug was increased to a total daily dose of 1000 mg over 2 weeks. He was on sulpiride for 20 mg lofepramine daily; 06/97: 5 mg olanzapine at night, 140 mg lofepramine daily; 06/97: 5 mg olanzapine at night, 140 mg lofepramine daily.

Quantitative neurological examination scores showing the progress of the movement disorder. 06/95: before trial sulpiride, no medication; 05/96: before risperidone, 20 mg paroxetine daily; 07/96: 1 mg risperidone four times daily and 20 mg paroxetine daily; 03/97: before re trialsulpiride, 20 mg paroxetine daily; 04/97: 400 mg sulpiride in the morning 600 mg at night and 20 mg paroxetine; 04/97: before olanzapine, 140 mg lofepramine daily; 06/97: 5 mg olanzapine at night, 140 mg lofepramine daily.

In the absence of a cure for Huntington’s disease, it is very important that any interventions considered enhance the quality of life of the patient and improve overall functioning. It may not always be in the best interests of the patient to use drug treatments for the movement disorder. In those patients who have severe movements, however, a trial of treatment may be appropriate and continued if a clear benefit has been achieved. Neurological monitoring and the patient’s own perception of the effect of the drug must be taken into account.

The mechanism by which olanzapine may have beneficial effects is unclear. Olanzapine has been shown to have high affinity for a large number of receptors including D1, D2, D4, 5HT2A, 5HT2C, 5 HT3, α-1-adrenergic, histamine H1, and 5 muscarinic receptors. This binding profile is similar to clozapine, another atypical antipsychotic drug, but substantially different to the conventional antipsychotic haloperidol.1 Preferential loss of D2 projection neurons which are involved in a feedback loop normally active in the suppression of involuntary movements is thought to be the pathophysiological basis of chorea in patients with Huntington’s disease.7 The D2 antagonist properties of olanzapine may explain its possible benefits in the improvement of chorea. However, the effect at other receptors such as D4 may also be important, as D4 receptor density has been shown to be raised in Huntington’s disease, therefore the D4/D2 ratio of activity may also be relevant. Differences in binding profile across a range of receptors may explain clinical differences in outcome when comparing different antipsychotic drugs.

This case report indicates that olanzapine may be a useful addition to the treatments for movement disorder, for some patients, and controlled trials of its use in Huntington’s disease would be welcome.

**Patient characteristics**

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age at surgery</th>
<th>Sex</th>
<th>Years with PD</th>
<th>H and Y*</th>
<th>UPDRS off/# pot/pallidotomy</th>
<th>Pallidotomy side</th>
<th>Transient side effects</th>
<th>Medication additional to levodopa</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>66</td>
<td>M</td>
<td>8</td>
<td>2/5</td>
<td>57/NP R</td>
<td>R</td>
<td>Slight facial paresis, swallowing problems, drooling</td>
<td>Trypsin, tetraxepam, alprazolam, apomorphine</td>
</tr>
<tr>
<td>2</td>
<td>43</td>
<td>F</td>
<td>7</td>
<td>2/2.5</td>
<td>22/7 L</td>
<td>L</td>
<td>Slight dysarthria</td>
<td>Trihexifenidyl</td>
</tr>
<tr>
<td>3</td>
<td>49</td>
<td>M</td>
<td>15</td>
<td>2/3</td>
<td>55/15 L</td>
<td>L</td>
<td>Facial paresis</td>
<td>Pergolide, amantadine</td>
</tr>
<tr>
<td>4</td>
<td>50</td>
<td>M</td>
<td>12</td>
<td>2/2</td>
<td>45/22 L</td>
<td>L</td>
<td>Slight dysarthria</td>
<td>Pergolide, selegiline</td>
</tr>
<tr>
<td>5</td>
<td>53</td>
<td>M</td>
<td>14</td>
<td>2.5/4</td>
<td>69/36 R</td>
<td>R</td>
<td>Facial paresis, hypophonia</td>
<td>Pergolide, selegiline</td>
</tr>
<tr>
<td>6</td>
<td>58</td>
<td>M</td>
<td>13</td>
<td>2/3.5</td>
<td>40/27 L</td>
<td>R</td>
<td>Facial paresis, anphasia</td>
<td>Pergolide, selegiline</td>
</tr>
<tr>
<td>7</td>
<td>61</td>
<td>F</td>
<td>15</td>
<td>2.5</td>
<td>55/NP R</td>
<td>R</td>
<td>Slight facial paresis, swallowing problems, drooling</td>
<td>Clozapine, tetraxepam, clonapride</td>
</tr>
</tbody>
</table>

H and Y=Hoehn and Yahr; UPDRS off=unified Parkinson’s disease rating scale part 3 (motor examination), in a standardised off state, 12 hours without antiparkinson medication; N P not performed.


**Transient hiccups after posteroventral pallidotomy for Parkinson’s disease**

Hiccups are defined as an abrupt intermittent, involuntary, contraction of the diaphragmatic and external (inspiratory) intercostal muscles, with inhibition of expiratory intercostal activity. This results in a sudden inspiration, abruptly opposed by closure of the glottis.1 Hiccups may result from various structural or functional disorders of the medulla, the afferent or efferent nerves to the respiratory muscles, and the gastrointestinal tract.1,2 Newson Davis performed a study of hiccups with electrophysiological techniques and concluded that hiccups is served by a supraspinal mechanism distinct from that generating rhyncbic breathing.3 The principal site of interaction of the hiccup discharge with other descending drives to the respiratory motoneuron is at the spinal level. Neurogenic hiccup is particularly associated with structural lesions of the medulla oblongata.

Since 1994 we have performed 66 pallidotomies for Parkinson’s disease in 60 patients. So far, we have seen transient hiccups in seven patients after the operation (table). Our target coordinates for the posteroventral globus pallidus at the border of the medial and lateral segments are 2–3 mm anterior to the midcommissural point, 5 mm below the intercommisural plane and 22 mm lateral to the midline of the third ventricle. Ventriculography was performed for target...
localisation. Patients started with a short schedule of corticosteroids (5 days) the night before surgery.

The hiccups started immediately after the operation or the next day, were intermittent, and the bouts of hiccup of six patients, with a duration of hours, resolved within 3 days after the procedure. One patient complained of yawning more often and frequent bouts of hiccup for 6 months.

Five patients were men. All patients were right handed. The mean age at surgery was 54 years and the mean duration of Parkinson’s disease was 12 years. All patients were taking levodopa. In four patients the hiccups appeared after a left sided pallidotomy. Patient 2 had a right sided thalamotomy 4 years before the pallidotomy. Patient 5 underwent a left sided pallidotomy 10 months before the right sided pallidotomy which caused the hiccups. The pallidotomies improved parkinsonism in the “off” state (table), contralateral dyskinesias, and pain accompanying Parkinson’s disease. Six patients had transient adverse events: four patients had a transient facial paresis postoperatively and two a slight transient dysarthria (table). Two patients had choreatic movements after the pallidotomy at the contralateral side which resolved spontaneously within 2 hours and is associated with a favourable surgical outcome.

Postoperative MR scans were obtained in the first six patients, and showed that in five patients the lesions were located in the posterior part of the globus pallidus pars externa (GPe) and interna (figure). In patient 5 the lesion was situated slightly more anterior in the GPe and putamen. In patient 3 there was a small separate lesion more dorsal, probably the GPe and putamen. In patient 5 the lesion was situated slightly more anterior in the globus pallidus or a neighbouring structure may be the lesion in the ventral medial segment of the globus pallidus or pressure, due to oedema, on an adjacent structure like the internal capsule or putamen. We could not find other reports of hiccups as an adverse event after functional stereotactic surgical interventions, nor after lesions of other aetiology involving the striatum. Based on our experience we hypothesise that the globus pallidus or a neighbouring structure may be involved in a supramedullary system involved in triggering hiccups.

R M A DE BIE
J D SPEELMAN
Department of Neurology

P R SCHUURMAN
D A BOSCH
Department of Neurorsurgery, Academic Medical Center, University of Amsterdam, The Netherlands

Correspondence to: Dr R M A de Bie, Department of Neurology, Academic Medical Center, PO Box 22700, 1180 DE Amsterdam, The Netherlands. Telephone 0031 20 566 3856; fax 0031 20 679 1438; email R.M.deBie@amc.uva.nl

5 Bathia KP, Marsden CD. The behavioral and motor consequences of focal lesions of the basal ganglia in man. Brain 1994;117:859–76.

Psychological adjustment and self reported coping in stroke survivors with and without emotionalism

Emotionalism after stroke is common, occurring in 10%–20% of a community sample. Psychological factors in its cause or maintenance have not been studied; research has tended to concentrate instead on location of the stroke lesion. We suspect that one reason for this neglect of psychological aspects of emotionalism is that most people do not make a distinction between emotionalism, and pathological crying and laughing. As a result all disorders of emotionality after stroke are stereotyped as being related to brain damage and therefore psychologically meaningless.

None the less, many patients with emotionalism describe their crying as provoked by emotionally congruent experiences, which makes the tearfulness seem understandable. In two previous studies we have shown that stroke patients with emotionalism have more symptoms of psychological disorder than do patients without emotionalism. In the present study, we explored further the psychological characteristics of stroke patients with emotionalism. Our aim was to determine whether they differed from patients without emotionalism in their psychological reactions to stroke, or in the coping strategies they reported.

Post-traumatic stress disorder is also characterised by recurrent episodes of intrusive and uncontrollable emotion, and we were therefore interested in whether patients with emotionalism also experienced thoughts typical of post-traumatic stress disorder. Because emotionalism is often described as uncontrollable, we were interested in the possibility that patients were more generally helpless, passive and receiving in their responses to stroke. Again, because of the reported uncontrollability of emotionalism, we postulated that patients with emotionalism would report a more external locus of control than those without emotionalism.

Participants were adults admitted to local general hospitals after stroke, and were interviewed within 1 month of admission. Exclusions were due to poor physical health, cognitive impairment, communication difficulties, or lack of consent. Approval for the study was obtained from the local research ethics committees.

All participants completed a standardised measure of distress—the general health questionnaire, GHQ-12; a widely used measure of intrusive thoughts of the sort encountered in post-traumatic stress disorder—the impact of events rating scale; a measure of cognitive coping—the mental adjustment to stroke scale (O’Rourke S, Dennis M, MacHale S, Slattery J. The development of the mental adjustment to stroke scale: reliability, patient outcome and associations with mood and social activity, manuscript in preparation); and a measure of beliefs about responsibility for recovery from illness—the recovery locus of control scale. All the measures are self report questionnaires.

A total of 177 stroke patients were screened, of whom 112 were excluded. The 65 participants (29 men, 36 women) had a mean age of 71.8 years (range 45 to 88 years). Nineteen (29.2%) patients met our criterion for emotionalism, a rate similar to that found in other studies. Their scores on the study measures are compared with the scores of patients without emotionalism in the table. It might be that these associations with emotionalism were accounted for by the greater general levels of distress experienced by those with emotionalism. We therefore undertook analysis of covariance with GHQ-12 and presence of emotionalism as the covariates, and each of the other test items in turn as the independent variable. The results showed an association, after adjustment for GHQ-12 score, between emotionalism and the impact of events subscales intrusion

Five months after left sided pallidotomy, MRI of patient 6: (A) transversal slice at the level of the anterior commissure and (B) 6 mm more ventral.
Comparison of stroke survivors with and without emotionalism, assessed in hospital 1 month after stroke

<table>
<thead>
<tr>
<th>GHQ-12*</th>
<th>No emotionalism (n=45)</th>
<th>Emotionalism (n=19)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mass</td>
<td>Mean (SD)</td>
<td>Mean (SD)</td>
</tr>
<tr>
<td></td>
<td>F=15.33, p&lt;0.001)</td>
<td>F=11.84, p&lt;0.001)</td>
</tr>
<tr>
<td>Recovery of control scale</td>
<td>3.2 (2.4)</td>
<td>5.3 (3.5)</td>
</tr>
<tr>
<td>Impact of events scale intrusion subscale**</td>
<td>33.2 (5.3)</td>
<td>34.1 (4.7)</td>
</tr>
<tr>
<td>Impact of events scale avoidance subscale*</td>
<td>2.9 (4.6)</td>
<td>9.2 (6.6)</td>
</tr>
<tr>
<td>MASS Fighting subscale</td>
<td>4.7 (4.6)</td>
<td>9.9 (6.1)</td>
</tr>
<tr>
<td>MASS Anxiety preoccupation subscale**</td>
<td>49.1 (4.0)</td>
<td>48.6 (4.2)</td>
</tr>
<tr>
<td>MASS Fatalism subscale*</td>
<td>22.2 (2.8)</td>
<td>25.2 (4.0)</td>
</tr>
<tr>
<td>MASS Avoidance subscale</td>
<td>20.0 (1.9)</td>
<td>21.3 (2.2)</td>
</tr>
<tr>
<td>MASS Helplessness/helplessness subscale**</td>
<td>1.7 (0.8)</td>
<td>1.9 (0.8)</td>
</tr>
<tr>
<td></td>
<td>10.9 (2.5)</td>
<td>14.1 (3.5)</td>
</tr>
</tbody>
</table>

MASS = Mental adjustment to stroke scale.
* p<0.05; ** p<0.01.

We thank those patients who participated in the study and the staff of local hospitals and the Leeds Stroke Database for their invaluable help. We also thank Dr Louise Dye for her statistical advice. This study was completed as part of work for the degree of DClinPsychol at Leeds University (SE).

PETER KNAPP
Stroke Outcome Study, Research School of Medicine, Leeds, UK

Correspondence to: Dr Allan House, Division of Psychiatry and Behavioural Sciences in Relation to Medicine, University of Leeds, 15 Hyde Terrace, Leeds LS2 9LT, UK.


Paraneoplastic stiff limb syndrome

Stiff man syndrome (SMS) is a rare, severe progressive motor disorder characterised by painful spasms, symmetric axial muscle rigidity, and uncontrollable contractions leading to distorted posturing. The disorder has been associated with the autoantigens, glutamic acid decarboxylase (GAD), and amphiphysin, which are cytoplasmic proteins in neurons of the CNS. A large series of patients with SMS found that most have antibodies against GAD,1 whereas amphiphysin is presumably the predominant autoantigen in paraneoplastic SMS.2 Recently, Barker et al.3 proposed that the nomenclature “stiff limb syndrome” refers to the focal form of SMS when one or more distal limbs are involved; two of their patients were also anti-GAD antibody positive, but none were tested for antibodies to amphiophysin or identified as having an underlying neoplasia. We present a patient clinically consistent with the stiff limb syndrome who was found to have autoantibody to GAD and breast cancer.

A 68 year old woman presented with a 1 month history of painful spasms in her legs. Cramps were associated with tactile stimuli and emotional upset. Within weeks, inversion began at the left and then right ankle, making ambulation difficult. Her medical history was significant for Graves’ disease treated with thyroxin and radioactive therapy, and hyperlipidaemia. She was a chronic smoker. General examination was noteworthy for lymphadenopathy in the right axilla. Her mental status was worse during periods of lower extremity spasms, during which she became anxious, diaphoretic, and tachycardic. Cranial nerve and motor evaluations were unremarkable, but assessment of the left leg, due to painful spasms elicited by light touch, was difficult. Inversion and plantar flexion were essentially fixed at the left ankle but could be overcome on the right. Deep tendon reflexes were 3+ in the upper and lower extremities, with sustained clonus at the right ankle. Sensory examination showed the exception of hyperaesthesia in the distal lower extremities, and coordination testing were grossly normal. No hyperlordosis or myoclonus was noted. Gait was limited due to ankle posturing.

The laboratory evaluation was noteworthy for a CSF with increased IgG indices (2.5, 3.4; normal, 0.2–0.8) and oligoclonal bands (5, 5) but no pleocytosis. Serological testing for anti-Hu, anti-Yo, and anti-Ri antibodies was unremarkable, and the haemoglobin A1C was 6.6 (5.6–7.7)%. Skin biopsy at three sites on the patient’s leg showed diminished epidermal nerve fibre density and terminal axonal swelling distally, consistent with a small fibre sensory neuropathy. The patient would not tolerate EMG. Magnetic resonance images of the brain and the entire spinal cord were normal. Fine needle aspiration of a soft tissue right axillary mass showed metastatic adenocarcinoma. On an open surgical procedure, infiltrating duct carcinoma of the breast was identified. Anti-GAD antibodies were positive at 1:640 by chemical assay and immunoprecipitation, but antibodies to amphiphysin were not detected by immunocytochemistry, immunoprecipitation, or western blotting (Dr P De Camilli, Yale University).

Ongoing therapy with clonazepam and a trial of oral dexamethasone did not improve the lower extremity symptoms. The patient’s ankle posturing continued a slow progression to marked inversion, with spastic inversion of hallucis longus. The patient died 18 months after symptom onset. Gross necropsy attributed the cause of death to aspiration pneumonia. Neuropathological examination showed a grossly normal spinal cord. Microscopically, the lumbar cord had mild reactive gliosis in the anterior horns but no evidence of inflammation. Sections of the frontal cortex, pons, and medulla showed mild diffuse reactive astrocytosis.

Stiff man syndrome is increasingly recognised as a heterogeneous disorder.4 Other case reports have documented patients with “focal” disease involving either lower or upper extremity posturing,5 which contrast...
with the "diffuse" axial and subsequent proximal muscle distribution of the classic disorder. Our patient differs from those reported with stiff leg syndrome in that an occult malignancy was present. Unfortunately, we were unable to obtain electrophysiological studies for comparison. The search for a paraneoplastic process was based on the findings of auxiliary lymphadenopathy and an abnormal CSF. Our patient is only the second reported patient with paraneoplastic SMS associated with anti-GAD antibody; the other had upper limb rigidity in the setting of breast cancer and additionally mounted an immune response to amphiphysin. Paraneoplastic processes can affect any component of the nervous system and, occasionally, multiple levels, as in the syndrome of sensory neuronopathy-encephalomyelitis. Our patient's findings were not entirely consistent with criteria for classic SMS in that an apparent encephalopathy and a small fibre neuropathy were identified—for example, her dysautonomia (tachycardia and relative hypertension) during spasms may have been a manifestation of involvement of small fibres. The role of autoantibodies in the pathogenesis of SMS and cancer is unclear. Via its probable function in endocytosis, amphiphysin has been postulated to play a part in the regulation of growth factor internalisation; however, the absence of an autoimmune response to this autoantigen in our patient suggests that other mechanisms of onconeogenesis in SMS exist. Given anecdotal evidence of improvement in paraneoplastic SMS after treating the underlying malignancy, we suggest that all patients with SMS, diffuse or focal, be screened for occult cancer.

ISAAC E SILVERMAN
Department of Neurology, Johns Hopkins University, Baltimore, USA

Correspondence to: Dr I E Silverman, Johns Hopkins University, Pathology 509, 600 North Wolfe Street, Baltimore, MD 21287, USA. Telephone 001 410 955 6626; fax 001 410 614 1008; email isesilver@jhmi.edu


Tetrotodin intoxication in a uraemic patient

Tetrotodin intoxication results from ingestion of puffer fish or other animals containing the toxin. Clinical presentation is mainly acute motor weakness and respiratory paralysis. Death is common in the worst affected victims. Although the severity of the symptoms generally depends on the amount of toxin ingested, it may be influenced by the victim's medical condition, as described in this report. The patient was a 52 year old uraemic woman. The uraemia was of undiagnosed etiology. Over the past 3 years she has received regular haemodialysis. One day both she and her husband, a healthy 55 year old man, ate a fish soup. About 4 hours after the meal she developed a headache and a lingual numbness at the distal parts of all four limbs. She was dizzy and unsteady, had difficulty in swallowing, and became very weak. She was taken to the emergency service and was placed on machine assisted ventilation as respiratory distress and cyanosis developed. Her husband remained asymptomatic throughout this time.

The patient's condition kept on deteriorating, developing eventually into a comatose-like state with no spontaneous or reflexive eye opening or limb movement within 30 minutes of intubation. On neurological examination, the pupillary light reflex was absent and oculocephalic manoeuvre elicited no ocular movements. All four limbs were areflexic and Babinski's signs were absent. Brain CT and laboratory studies of arterial blood gas (under assisted ventilation), electrolytes, liver function, blood glucose, and CSF study were unremarkable. An examination of renal function indicated chronic renal insufficiency with mild azotaemia (urea nitrogen 70 mg/dl, creatinine 9.1 mg/dl). An EEG, recorded 18 hours after the onset of symptoms when the neurological condition was unchanged, showed posterior dominant alpha waves intermixing with trains of short duration, diffuse theta waves. When brief noxious stimuli were applied to the sternum, they were replaced transiently by beta activities. The findings suggested that the profound neurological dysfunction might be peripheral in origin. The patient was given a course of haemodialysis according to the set schedule for uraemia at 21 hours after onset of the symptoms. Her condition improved dramati-
cally within an hour. She could open her eyes and she communicated and answered questions correctly by blinking. Pupillary reflex recovered and voluntary eye movements were limited only at the extreme lateral gaze. Muscle power was grade 3 and 4 in the proximal and distal parts of the four limbs. Tendon reflexes were still absent. She was taken off mechanical ventilation the next day. Her clinical condition continued to improve and her symptoms subsided in a stepwise pattern, in response to each course of haemodialysis (figure). When recalling, she could remember certain events such as the recording of the EEG, but was “too weak to move” at that time. She regained her initial strength by the time she was discharged on day 16.

When analysing the remains of the cooked fish (identified as *Yongieichthys nebulosus*), tetrodotoxin was demonstrated by thin layer chromatography, high performance liquid chromatography, and cellulose acetate membrane electrophoresis. Toxicity was assessed by using Institute of Cancer Research strain adult male mice and the toxicity score was 25 mouse units (MU)/g in fish muscle (1 MU = 0.178 µg in the ICR strain mouse).1

Tetrodotoxin exerts its effect through binding with and blocking the voltage dependent sodium channel.2 The voltage clamp experiments showed that tetrodotoxin diminished the sodium inward current responsible for the depolarisation of excitable membrane. The gating properties of the sodium channel, such as the activation and inactivation mechanism, are not altered—that is, the sodium channel is not permanently damaged and its function recovers when the bound toxin is released. In uraeinia, ion conductance through the sodium channel is also impaired. Sodium permeability through excitable membranes is reduced and small inward sodium current and reduced action potential amplitudes are noted in experimental uraemic neuropathy.3 By contrast with the effects of tetrodotoxin, uraemia changes the basic property of the sodium channel by an increased inactivation and an impaired activation mechanism. The excitability of peripheral nerves will be more significantly depressed when these two conditions coexist. The synergistic effect of uraemia and tetrodotoxin is obvious in this incident in which the patient and her husband ingested roughly an equal amount of tetrodotoxin (over 200 µg, calculated from toxic score times the weight of ingested fish). The amount is about 10% of the estimated lethal dose in humans—2200 µg/60 kg body weight (body weights of the patient and her husband were 54.5 and 62 kg respectively)—and caused no clinical evidence of poisoning in the healthy person. It was of interest that the CNS was relatively spared from the toxicity as the EEG showed a posterior dominant, particularly those who show intractable ventilator dependence. All the measures used to prevent ventilator failure were of little help. However, when the patient recovered, the patient retained consciousness when the symptoms were at their most severe.

One of the most striking clinical features in our patient was the response to haemodialysis. Despite a small amount of tetrodotoxin on ingested, the dramatic improvement of her clinical condition was most likely attributed to the rapid elimination of absorbed toxin in the course of haemodialysis, rather than spontaneous recovery. The physical and chemical properties of tetrodotoxin are also supportive to this hypothesis.4 It has a low molecular weight (C₄H₇N₃O₈), is water soluble, and not significantly bound to protein—all these features are found in toxins amenable to haemodialysis. Traditionally, the management of tetrodotoxin intoxication is mainly supportive, such as gastric lavage to remove unabsorbed toxin and machine assisted ventilation when respiration is severely affected. We suggest that haemodialysis may be an effective method in the treatment of tetrodotoxin intoxication.

MIN-YU LAN
SHUNG-LON LAI
SHUN-SHENG CHEN
Department of Neurology, Kaohsiung Medical College, Kaohsiung City, Taiwan

DENG-FWU HWANG
Department of Food Science, National Taiwan Ocean University, Keelung City, Taiwan

Correspondence to: Dr Shun-Sheng Chen, Department of Neurology, Kaohsiung Medical College Hospital, 100 Shih-Chung 1st Road, Kaohsiung City 807, Taiwan. Telephone 00886 7 3121101 ext 6771; fax 00886 7 3234237; email sheng@mail.nsysu.edu.tw


Relation between critical illness polyneuropathy and axonal Guillain-Barré syndrome

The clinical entity critical illness polyneuropathy occurs almost exclusively in patients in critical care units and has been characterised as a complication of sepsis and multiple organ failure.1,2 Critical illness polyneuropathy may be a common cause of the difficulty in weaning patients from the ventilator, particularly those who show intractable ventilator dependence. All the measures used to prevent ventilator failure were of little help. However, when the patient recovered, the patient retained consciousness when the symptoms were at their most severe.

One of the most striking clinical features in our patient was the response to haemodialysis. Despite a small amount of tetrodotoxin on ingested, the dramatic improvement of her clinical condition was most likely attributed to the rapid elimination of absorbed toxin in the course of haemodialysis, rather than spontaneous recovery. The physical and chemical properties of tetrodotoxin are also supportive to this hypothesis.4 It has a low molecular weight (C₄H₇N₃O₈), is water soluble, and not significantly bound to protein—all these features are found in toxins amenable to haemodialysis. Traditionally, the management of tetrodotoxin intoxication is mainly supportive, such as gastric lavage to remove unabsorbed toxin and machine assisted ventilation when respiration is severely affected. We suggest that haemodialysis may be an effective method in the treatment of tetrodotoxin intoxication.

MIN-YU LAN
SHUNG-LON LAI
SHUN-SHENG CHEN
Department of Neurology, Kaohsiung Medical College, Kaohsiung City, Taiwan

DENG-FWU HWANG
Department of Food Science, National Taiwan Ocean University, Keelung City, Taiwan

Correspondence to: Dr Shun-Sheng Chen, Department of Neurology, Kaohsiung Medical College Hospital, 100 Shih-Chung 1st Road, Kaohsiung City 807, Taiwan. Telephone 00886 7 3121101 ext 6771; fax 00886 7 3234237; email sheng@mail.nsysu.edu.tw


Critical illness polyneuropathy

Axonal Guillain-Barré syndrome

Critical illness polyneuropathy invariably occurs at the peak of critical illness and sepsis, but in Guillain-Barré syndrome there is a brief period of recovery after a relatively minor illness or inoculation. Except for differences in the predisposing causes, as Boltot et al3 reported, it is difficult to distinguish critical illness polyneuropathy from Guillain-Barré syndrome purely clinically. In both, polyneuropathy runs a monophasic course, the onset being relatively acute but with subsequent improvement in most instances. The clinical features also are similar; evidence of muscle weakness in all four limbs, occasional involvement of facial muscles and frequent involvement of the muscles of respiration, the depression or absence of deep tendon reflexes, and some evidence of distal sensory loss.

The first step by Bolton et al4 in determining exact aetiology was to differentiate critical illness polyneuropathy from Guillain-Barré syndrome. In reviewing the patients with critical illness polyneuropathy and Guillain-Barré syndrome who were studied in their EMG laboratory, they found marked differences between the two types of polyneuropathy. Patients with Guillain-Barré syndrome had greater slowing of the speed of impulse conduction, and, in the initial stages, abnor-
of acute diarrhoea, commonly precedes the development of Guillain-Barré syndrome. There is a close association between axonal Guillain-Barré syndrome and antecedent C jejuni infection. The antecedent infectious symptom was diarrhoea in three of five pivotal axonal Guillain-Barré syndrome described by Feasby et al. Observations by Griffin et al confirmed that AMSAN follows C jejuni infection. Serum samples from patients with axonal Guillain-Barré syndrome subsequent to C jejuni enteritis often bear the class autoantibodies to gangliosides GM1, GM1b, GD1a, or GalNAc-GD1a in the acute phase of the illness, and there is molecular mimicry between these gangliosides and the lipopolysaccharides of C jejuni isolates from patients with Guillain-Barré syndrome. This ganglio-side mimicry may trigger high production of the IgG anti-ganglioside antibodies, and these autoantibodies may cause motor nerve dysfunction in patients with GBS.

Interestingly, Hagensee et al reported a case of “C jejuni bacteremia and subsequent Guillain-Barré syndrome” that occurred in a patient with chronic graft versus host disease and prompt the narrow transplantation. Because there was acute flaccid paralysis associated with sepsis, some physicians might have diagnosed critical illness polyneuropathy. Conversely, the existence of this case strongly suggests that some diagnosis of critical illness polyneuropathy should actually be axonal Guillain-Barré syndrome or AMSAN. Our hypothesis of the nosological relation between critical illness polyneuropathy and Guillain-Barré syndrome is shown in the figure. Serum IgG antibodies against GM1, GM1b, GD1a, or GalNAc-GD1a could be used as immunological markers for axonal Guillain-Barré syndrome. To examine the aetiology of critical illness polyneuropathy and its nosological relation to axonal Guillain-Barré syndrome, it is necessary to investigate whether patients with critical illness polyneuropathy have anti-ganglioside antibodies during the acute phase of the illness.

NOBUHIRO YUKI KOICHI HIRATA
Department of Neurology, Dokkyo University School of Medicine, Japan
Correspondence to: Dr Nobuhiro Yuki, Department of Neurology, Dokkyo University School of Medicine, Kitakobayashi 880, Mibu, Shimotsuga, Tochigi 321-0293, Japan.

Repetitive transcranial magnetic stimulation in the treatment of chronic negative schizophrenia: a pilot study

Recently, a new technology known as repetitive transcranial magnetic stimulation (RTMS) has been developed. In 1994, the use of magnetic stimulation in clinical psychiatry was suggested. Since then, it has been used in the study or treatment of obsessive-compulsive disorder, conversion disorder, schizophrenia, and particularly, depression. Our pilot study aimed to assess the possible adverse effects of this treatment in chronic schizophrenic patients with severe negative symptoms; to evaluate if direct RTMS of the prefrontal cortex might improve negative symptoms or cognitive impairments in patients with chronic schizophrenia; and, thirdly, to note if RTMS might modify the deficit in prefrontal cortical activity, often reported to be hypofrontal in schizophrenia, particularly under conditions of task activation.

Six right-handed patients with chronic schizophrenia were identified at the outpatient psychiatric service of the Hospital Clinic of Barcelona. There were two men and four women (mean age 39).

Exclusion criteria included alcohol or substance abuse dependence disorder in the past 5 years, focal neurological symptoms, systemic neurological illness, taking cerebral metabolic activator or vaso-dilator medications, electro-convulsive therapy within 6 months, and significant abnormal findings on laboratory examination.

All patients were taking neuroleptic drugs, but a stable dose for at least 3 months was required. All patients were studied off benzodiazepines for at least 1 week before beginning the treatment. During the RTMS, psychotropic medications were continued at the initial dosage.

All patients were admitted to hospital. Inpatients underwent the UKU side effect scale, the positive and negative syndrome scale, and a neurological battery, the day before beginning the treatment and at the end of the treatment. The UKU scale was also administered after each session.

An equivalent neuropsychological battery was used on both occasions, which consisted of the block design test of the Wechsler adult intelligence scale, the trail making tests A and B, the FAS verbal fluency test, and two subtests of the Wechsler memory scale (the visual memory reproduction and the verbal paired associates subtests).

A brain SPECT study was performed by rotating a dual head gamma camera, fitted with high resolution fanbeam collimators. Two “n”Tc-HMPAO SPECT scans with cognitive activation, such as the Wisconsin card sorting test (WCST), were performed on each patient (24 hours before the beginning of the treatment and at the end of the treatment). The UKU scale was also administered after each session.

Another neuropsychological battery was used on both occasions, which consisted of the block design test of the Wechsler adult intelligence scale, the trail making tests A and B, the FAS verbal fluency test, and two subtests of the Wechsler memory scale (the visual memory reproduction and the verbal paired associates subtests).

A brain SPECT study was performed by rotating a dual head gamma camera, fitted with high resolution fanbeam collimators. Two “n”Tc-HMPAO SPECT scans with cognitive activation, such as the Wisconsin card sorting test (WCST), were performed on each patient (24 hours before the beginning of the treatment and at the end of the treatment).

RTMS was given with a Mag Pro magnetic stimulator for 5 days a week, 5 days a week, for 2 weeks, at a dosage of 20 Hz for 2 seconds, once per minute for 20 minutes at 80% motor threshold.

A motor threshold was determined by visualisation of finger movement. A butterfly magnetic coil was placed tangential to the orbital area, on the C3 and C4 EEG point.

An important finding of this study was that RTMS may be given to stable schizophrenic patients without exacerbating their psycho-

Table: Neuropsychological tests and PANSS scores

<table>
<thead>
<tr>
<th>Test</th>
<th>Mean (SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Block design</td>
<td>Pre 49 (11.95) NS</td>
</tr>
<tr>
<td>Trail making test A</td>
<td>Pre 38.5 (10.6) NS</td>
</tr>
<tr>
<td>Trail making test B</td>
<td>Pre 38.3 (4.5) NS</td>
</tr>
<tr>
<td>Immediate visual reproduction</td>
<td>Pre 41 (10.03) NS</td>
</tr>
<tr>
<td>Delayed visual reproduction</td>
<td>Pre 50.5 (4.82) NS</td>
</tr>
<tr>
<td>Immediate verbal paired associates</td>
<td>Post 54.8 (11.2) NS</td>
</tr>
<tr>
<td>Delayed verbal paired associates</td>
<td>Post 46.18 (2.3) NS</td>
</tr>
<tr>
<td>PANSS-P</td>
<td>Post 53.8 (11.8) NS</td>
</tr>
<tr>
<td>PANSS-N</td>
<td>Post 54 (7.46) NS</td>
</tr>
<tr>
<td>PANSS-G</td>
<td>Post 59.5 (10.03) NS</td>
</tr>
<tr>
<td>PANSS-Total</td>
<td>Post 8.8 (1.1) NS</td>
</tr>
<tr>
<td>PANSS-Positive</td>
<td>Post 8.8 (1.17) NS</td>
</tr>
<tr>
<td>PANSS-Negative</td>
<td>Post 36.5 (11.47) NS</td>
</tr>
<tr>
<td>PANSS-G General</td>
<td>Post 31.67 (8.26) p&lt;0.02</td>
</tr>
<tr>
<td>PANSS-G General</td>
<td>Post 27.83 (8.47) NS</td>
</tr>
<tr>
<td>PANSS-P</td>
<td>Post 16.83 (7.28) NS</td>
</tr>
<tr>
<td>PANSS-G Total</td>
<td>Post 15.33 (7.55) NS</td>
</tr>
</tbody>
</table>

Pre=preatreatment; Post=post-treatment; PANSS=positive and negative syndrome scale; FG=general psychopathology scale; NG=negative scale; P=positive scale.
Sensory alien hand syndrome

The case report by Ay et al of alien hand syndrome and review of the literature neglected the intriguing issue of why in every case so far reported the patient seems to be terrified of the alien limb. Not believing that you are any more in control of a limb is not likely to be a pleasant experience.

Those with alien hand syndrome seem to jump to extremely negative conclusions concerning the intent of the limb. Typically, as in the report of Ay et al, the common belief is that the limb has deeply malevolent intentions towards the victim.

It is this aspect of alien hand syndrome that I suggest also incorporates into its neurological explanations, and which provides a clue as to why our everyday experience of being in charge of our bodies, and so initiating all personal action, itself has a neurological basis. In other words, while the brain is the seat of all our consciousness and experiences, there is also a part of our nervous system which is responsible for our belief that we have free will over our behaviour. Patients with alien hand syndrome think that they are no longer in control of a limb because the brain is the seat of all our actions and experiences.

Defenders of human “free will” argue what happens before the brain itself decides to act is merely a prelude and that the part of the brain that normally works to help us make our actions conscious awareness. The authors reply: “Defenders of human “free will” argue what happens before the brain itself decides to act is merely a prelude and that the part of the brain that normally works to help us make our actions conscious awareness. The implication of those who experience the syndrome might not be an incidental finding, but a core aspect of the disorder.”

The authors reply: “We appreciate Persaud’s comments regarding the alien hand syndrome, “the perceived malevolence of the affected limb towards our victim, and the question of whether with loss of the conscious sense of voluntary control over our bodies, our minds... decide that if ourselves are not in control then someone or something else must be”. We would offer that the value of our particular case is that it was due to a central deafferentation—therefore the term “sensory alien hand syndrome”. As
opposed to the idea that “we know our limbs belong to us because they obey us”, we know that our limbs belong to us because they provide us with sensory input that is recognised as self. Many patients with movement disorders or paralysis lose control of their limbs but still have no difficulty in realising them as self. Indeed even in “phantom limb” there is sense of self due to central processes in the absence of a limb. Our patient, as do others with anosognosia and primary abnormalities of central sensory systems, shows perhaps that it is central sensory processes that are the key to identifying “self”. We know our limbs not because they obey us but because they have a pattern of sensory stimulation that accompanies our own limb movements. When this pattern never reaches specific cortical regions, then the limb is not perceived as self; called “amorphanalysis” by Denny-Brown and Banker 1.


Vasomotor reactivity is exhausted in transient ischaemic attacks with limb shaking

The article of Baumgartner and Baumgartner entitled “Vasomotor reactivity is exhausted in transient ischaemic attacks with limb shaking” 2 provides interesting new information regarding the nature of involuntary limb movements contralateral to haemodynamic failure from severe carotid artery occlusive disease. The authors evoke an “exhausted cerebral vasoreactivity in the hemispheres opposite the involuntary limb movements”. In their report, involuntary movements affected only the limbs, and displayed no tonic contraction, tonic-clonic jerking, or Jacksonian march and no epileptic activity during attacks. These findings led the authors to strongly argue against seizures as the cause of limb shaking in these transient ischaemic events.

In contradistinction, a 72 year old right handed man admitted to our hospital with a 3 month history of episodic weakness and numbness of the right arm. The patient then had six discrete stereotypic episodes of right arm weakness and clumsiness that were also associated with weakness in speaking. Several episodes of dysarthria, numbness and weakness of the right arm and leg (MRC grade 4/5) were seen, unrelated to posture, some of which occurred when the patient was supine. Movements were characterised by slight tremulousness and asterixis-like movements of the outstretched right arm. There was a return to baseline functioning between events. 3 Video-EEGing, however, showed low voltage spikes in the left central-parietal head regions contralateral to the facial twitching and the right arm and right leg weakness. Although ongoing clinical and EEG seizures activity stopped, attacks still occurred after 2 mg intravenous lorazepam, reoccurred after loading with phenytoin. Because angiography disclosed a greater than 95% stenosis of the left internal carotid artery (while the patient was treated with phenytoin at a concentration of 16.5 mg/l), the patient was anticoagulated with heparin, but episodes continued. It was only after a left carotid endarterectomy that all episodes of weakness, tremulousness, and EEG epileptiform activity stopped. They have not recurred over the past 5 years.

Unlike our case of limited duration, the persistence of alien hand syndrome forms dependent on mesial frontal dysfunction. These patients rarely deny that the affected limb belongs to them. Instead, they understand it in terms of their “anarchic hand”. Hence, although the initial syndrome may result in disjointed and terrifying perceptions, it seems that the brain quickly re-establishes its control by presently undefined adaptive capacities. Furthermore, why it almost exclusively involves the left body side in right handed people remains unknown. Studying this syndrome in greater detail may yield additional insights into the pathophysiology of denial and misidentification.

HAKAN AY
FERDINANDO BUONANNO
DEAN A LE
WALTER J KOROSHETZ
Department of Neurology, Stroke Service, Massachusetts General Hospital, Harvard Medical School, 32 Fruit Street, Boston MA 02114, USA
BRUCE H PRICE
Department of Neurology, McLean Hospital, 115 Mill Street, Belmont MA 02178-9106, USA


Baumgartner and Baumgartner reply: We are grateful for the response of Kaplan to our short report. We agree that somatic inhibitory seizures may mimic transient ischaemic attacks (TIAs). Such TIAs are associated with negative symptoms such as sensorimotor deficits and difficulty with speaking, EEG evidence of seizure activity, and cessation of the TIAs after the administration of an anticonvulsant drug. 4 Limb shaking TIAs, however, differ from TIAs related to inhibitory seizures in several ways. (1) They are associated with positive phenomena (limb shaking), and the involuntary movements do not affect the facial musculature. Patients with attacks of shaking movements of the limbs have no EEG evidence of epileptic activity, and involuntary movements do not stop after administration of anticonvulsant therapy. (3) Although the patient presented by Kaplan had a 95% stenosis of the left internal carotid artery, it is unclear whether haemodynamic failure was present or not, because no studies evaluating the haemodynamic reserve in the homolateral hemisphere were presented. This is in accordance with the finding that the involuntary movements as well as the sensorimotor deficits of Kaplan’s patient were not related to paroxysmal (4) The pathogenesis of TIAs related to TIAs may be due to disinhibition of subcortical control mechanisms as a result of ischaemia. In our opinion, it is not clear whether the asterixis-like movements of the outstretched right arm of Kaplan’s patient are due to epileptic seizures, because unilateral asterixis of the outstretched arm has been reported with contralateral vascular lesions affecting almost all cerebral structures involved in the homolateral hemisphere including ischaemia in the territory of the middle cerebral artery. 5

RALF W BAUMGARTNER
Department of Neurology, University Hospital of Zürich, Switzerland

IRIS BAUMGARTNER
Division of Angiology, University Hospital of Bern, Switzerland

Correspondence to: Dr Ralf W Baumgartner, Neurológische Klinik, Frauenklinikstrasse 26, CH-8091 Zürich, Switzerland. Telephone 0041 1 255 56 86; fax 0041 1 255 43 80; email strub@neurol.unizh.ch

BOOK REVIEWS


To the MRCP candidate neurology is one of the more daunting specialties. The unfamiliar nerve conduction study and the frankly mysterious EEG can distress an otherwise well rounded senior house officer. Despite the fact that much of neurology is commonly seen on a general medical ward—strokes, dementias and so forth—the general perception is of an unimaginable list of eponymous syndromes and obscure signs. Rather than dwell on the last, in this book Dr Smith tries to address the commoner complaints as examination style questions each with a “simple clinical les-


This book, after a short introduction to some of the fundamental features of the disease goes on to provide some 117 illustrations of aspects of the disease from Cruveier’s plates to histopathological specimens and also a heavy leaning to imaging particularly magnetic resonance imaging, as might be expected. There is no doubting the aesthetic impact of this short book. In addition, the fact that these illustrations emanate from a well established figure in the multiple sclerosis world and are likely to be a representative set of personal teaching slides from a successful academic career all vouch for the provenance and informative nature of the atlas. However, the place of such a book within a neurologist’s library has to be questioned. There are a plethora of high quality textbooks devoted to all aspects of multiple sclerosis all well illustrate-


Transcranial colour duplex sonography is an ultrasonic technique which is becoming increasingly available for the non-invasive imaging of intracranial structures, particularly the basal cerebral arteries. There are now four principal components to the technique: B mode ultrasound which can be used to image the brain parenchyma; colour coded Doppler which provides a colour image of the basal vessels; spectral analysis of pulsed wave Doppler which is used to derive blood flow velocities; and latterly “power” Doppler which is also used to provide an averaged following analysis of the amplitude rather than the frequency of the reflected ultrasound beam. In addition, echocontrast agents are now available which can increase the signal to noise ratio and thus help overcome some of the detrimental acoustic effects of the skull.

This volume of 400 pages and liberal colour diagrams and prints is edited by three exponents of the technique. Thirty one chapters contain a further 180 pages which may be topics from the history of transcranial ultrasound, through the physics of Doppler ultrasound to potential clinical applications. The book is helpfully split into two sections with the theoretical aspects describing the first half and clinical aspects in the second.

This is certainly a specialised book and will really only appeal to those interested in, or wishing to develop, expertise in transcranial colour coded ultrasound. However, the technical chapters are not a vehicle to the clinical chapters on instrumentation, signal processing, echocontrast agents, harmonic imaging etc will certainly provide a comprehensive understanding of the principles behind the technique. I think that some of the errors made in the interpretation of vascular ultrasound examinations are due to an incomplete understanding of the physics of Doppler ultrasound, hence the attention paid to this area is commendable.

The clinical section covers the examination technique, normal reference values, the main categories of cerebrovascular disease, and also contains chapters on areas which may be less immediately suitable for ultrasound study. For example, the findings in head trauma, tumours, psychiatric disorders, and movement disorders are the subject of separate chapters. Although I have no problem with enthusiasm for this technique a little pragmatism would not go amiss. A more balanced discussion of the limitations as well as potential of the technique could have been applied.

As with any book with multiple authors there is some variation in style and overlap, particularly in the introductions and conclu-
sions of the chapters. Nevertheless, it is a comprehensive current review of transcranial colour coded sonography. Although the reader must decide exactly how this technique fits into clinical practice the book will certainly stimulate some ideas.


This is volume 47 of a series entitled Neurological Disease and Therapy, series editor W C Koller. This volume is edited by an American surgeon and two British neurophysiologists. Most of the 45 contributors are American or British, almost half of whom, including Dr Cole, are from Southampton. The book begins with a pathophysiological
introduction setting the scene for the five main disease sections covering developmental/genetic disease, spinal injury, infection, tumour, and the effect of neurological and systemic disease on the spinal cord. This chapter covers a wide area from multiple sclerosis to motor neuron disease to vascular disease to metabolic diseases. Then follows a section on investigation considering imaging, neurophysiology, and urodynamics. Finally, there is a miscellaneous section covering clinically important entities such as pain, sexual problems, and terminal care associated with spinal cord disease but also including a highly specialised chapter on the role of oriental rashes in spinal cord injury.

This is an ambitious attempt at being comprehensive. The editors themselves worry that the emphasis favours surgical conditions. Although this might be the case, many surgical chapters are written by the neurosurgeon or rheumatologist, care for spinal disease often falling between several specialties. Therefore, it is of benefit to the clinician to have all aspects of spinal disease in one volume. The standard and style of the individual chapters varies, that on motor neuron disease being up to date and topical, malignancies being covered in depth. That on sexual problems associated with spinal cord disease is excellent, particularly practical and a must for both doctors dealing with spinal disease and for patients themselves who are often unInformed (our fault, not theirs). The chapter on depression illness will be food for thought for many doctors who enjoy recreational diving, for although studies have not yet shown adverse affects on the quality of life in those who dive frequently but without incident, there is evidence for cumulative neurological damage from neurophysiological, imaging, and pathological studies is compelling.

The quality of illustration is high. Perhaps not surprisingly, this is particularly evident in the imaging section (where there is a rather spectacular sagittal T2 weighted MRI of a intramedullary arteriovenous malformation). In addition to imaging many of the chapters also make good use of schematic diagrams and line drawings to enhance the text.

Drs Engler, Cole, and Merton end their preface by commenting that “Our main hope, however, is that the chapters will read as a series of views on the spinal cord and its disease, so that a surgeon may learn about current practice as well as the wide range of conditions affecting the cord that are outside the field of surgery”. While I agree that educating surgeons is an admirable aim, I think that the authors rather undersell themselves and that this book’s main strength, as I have said above, is that it will appeal to all disciplines that deal with spinal cord disease, bringing together neurological, rheumatological, and surgical disease that is often covered in separate textbooks.

GILLIAN HALL


This is the second time that I have been asked to review a book on this topic. The first time I approached the task with some scepticism - were neurological diseases in women really so different from those in men that they warranted their own text book? But I rapidly became a convert to the cause, being reminded that there are issues specific to females that influence both disease, investigation, and treatment (pregnancy, breast feeding, menopause, to name the most obvious) and that not all neurological diseases affect the sexes equally. There are also wider socio-economic and legal issues that play a part in the complete disease picture which many of us neglect too often but which this book is careful to address (see below). Leaving content aside for a moment, this is a beautifully presented book; clearly headed and with wide use of well constructed tables. It encourages one to read on. It seems up to date and well referenced.

The contributors (40 in total) are exclusively American, and east coast American at that with only occasional forays westward. The text is divided into three sections. The first, entitled General Issues in Women includes an anatomical chapter considering the sex differences of regional brain structure and function. More novel for this type of text, it contains two thoughtful chapters considering women’s health within the context of their lifestyles and women’s health and its relation with the law. This chapter considers issues such as coercive approaches to preventing foetal harm, those relating to informed consent to medical treatment, and difficult choices with neurological implications. The law and the case examples are exclusively American but the issues are universal. This opening section leaves no doubt that this is a book that has taken female issues extremely seriously.

The second section looks at neurological diseases as they affect females at different life stages, from birth through menarche, pregnancy, and menopause, to the elderly woman. As well as considering genetic diseases that strike at a particular age, these chapters consider the influence of changing physiology and hormonal balance on neurological disease. The third section is the most conventional. Each chapter considers a neurological disease representing these diseases with emphasis on their effect on women and there is, by necessity, some overlap between this and the previous section. As a non-American, I would feel more comfortable to believe that the high number of female patients with peripheral nerve injuries secondary to physical beatings, knife wounds, or gunshot wounds reflected the country of origin of this book!

If pushed to criticise, the indexing could be more complete and certain conditions considered in more detail, in particular, paraneoplastic conditions associated with breast and gynaecological malignancies. However, that aside, I think this a rather special book and not only a good addition to any neurological library but a useful purchase for anyone interested in female medical issues.

GILLIAN HALL

**The reader may be interested in the following:**


---

**CORRECTION**


During the editorial process the descriptions of the histograms in figure 4 (p 614) were wrongly ascribed. The corrected figure is reproduced below.

**Figure 4** Correlation of clinical response (grade 0 or 1 response indicates non-responders, grade 2 response indicates reduced response, and grade 3 or 4 are responders) with response to test injections.
Transient hiccups after posterovertral pallidotomy for Parkinson's disease

R M A DE BIE, J D SPEELMAN, P R SCHUURMAN and D A BOSCH

doi: 10.1136/jnnp.67.1.124

Updated information and services can be found at:
http://jnnp.bmj.com/content/67/1/124

These include:

References
This article cites 3 articles, 3 of which you can access for free at:
http://jnnp.bmj.com/content/67/1/124#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/